Show/Hide Menu

Management

Open and complete information on a routine basis is a guiding principle for the cooperation of MorphoSys’s Management Board and Supervisory Board. They work closely together and make decisions for the benefit of the company. Their stated objective is the sustainable increase in the company’s value.

Management Board

MorphoSys was co-founded in 1992 by today's CEO, Dr. Simon Moroney. Through the joint effort of the entire Management Board, the company has become one of the leading biopharmaceutical companies worldwide.

Dr. Simon E. Moroney

Chief Executive Officer

Biography

Dr. Simon E. Moroney

Chief Executive Officer

Year of Birth 1959
Nationality

German / New Zealand

Management Board Member of MorphoSys AG since 1999
End of appointment 2020

Dr. Moroney is one of the Company’s co-founders. Prior to that, Dr. Moroney held positions in the Department of Pharmacology, University of Cambridge, UK, as Assistant Professor in the Chemistry Department of the University of British Columbia, Vancouver, Canada, and as Associate in the Chemistry Department of the ETH in Zurich, Switzerland, where he also held a position as Lecturer. He was an Associate in the Harvard Medical School, Boston, USA, and an employee of ImmunoGen Inc., where he worked on the first generation of anti-cancer antibody conjugates.

Dr. Moroney studied chemistry in his native New Zealand, where he completed an MSc with 1st class honors and was a Commonwealth Scholar to the University of Oxford, where he was awarded a D.Phil. in Chemistry.

In 2002, Dr. Moroney received the German Cross of the Order of Merit by Dr. Johannes Rau, President of the Federal Republic of Germany, for his services to the biotechnology industry.

Dr. Moroney currently does not hold any other board memberships.

Jens Holstein

Chief Financial Officer

Biography

Jens Holstein

Chief Financial Officer

Year of Birth 1963
Nationality German
Management Board Member of MorphoSys AG since 2011
End of appointment 2020

Jens Holstein joined MorphoSys from Fresenius Kabi AG, where he most recently served as Regional CFO for the region EME (Europe/Middle East) and as Managing Director of Fresenius Kabi Deutschland GmbH. Over the last almost 16 years at Fresenius he had held a variety of financial and general management positions. From 2006 to 2010, he was Regional Chief Financial Officer of Fresenius Kabi Asia Pacific Ltd., based in Hong Kong. Prior to this appointment, Mr. Holstein was Managing Director of Fresenius ProServe GmbH and Finance Director and Labor Director of the company's subsidiary Wittgensteiner Kliniken AG. Earlier positions within Fresenius included General Manager of hospitalia care GmbH, Commercial Manager of the Projects & Service business unit of Fresenius AG and Commercial Manager of hospitalia international GmbH. Prior to joining Fresenius, Mr. Holstein spent several years in the consulting industry, with positions in Frankfurt and London.

Mr. Holstein holds a Diploma in Business Administration from University of Münster.

He currently does not hold any other board memberships.

Dr. Malte Peters

Chief Development Officer

Biography

Dr. Malte Peters

Chief Development Officer

Year of Birth 1962
Nationality German
Management Board Member of MorphoSys AG since 2017
End of appointment 2019

Dr. Peters joined MorphoSys from Sandoz International, Holzkirchen, Germany, where he was Global Head of Clinical Development of the Biopharmaceuticals Business Unit. Prior to this position, he served as Clinical Head and Site Head for Basel and East Hanover in the department of Oncology Translational Medicine at Novartis. Dr. Peters held teaching appointments in Internal Medicine and Biochemistry at the University of Mainz, Germany.

Dr. Peters received his MD degree from the Freie Universität Berlin, Germany, and was trained at the Universities of Padova, Italy and Bochum and Berlin, Germany. After scientific work at different universities he received his habilitation in Internal Medicine at the University of Mainz, Germany. Subsequently, he served as Research Scientist at the Amgen Research Institute in Toronto, Canada, as Director of Cancer Research at Merck KgaA in Darmstadt, Germany and as Medical Director at Micromet AG in Munich, Germany.

Dr. Peters currently does not hold any other board memberships.

Dr. Marlies Sproll

Chief Scientific Officer

Biography

Dr. Marlies Sproll

Chief Scientific Officer

Year of Birth 1958
Nationality German
Management Board Member of MorphoSys AG since 2005*
End of appointment 2020

*temporary leave since April 15, 2017 for a period of initially six months

Dr. Sproll joined MorphoSys as R&D department head in 2000. In 2005, she was promoted to Chief Scientific Officer. Her current areas of responsibility include technology development, discovery, manufacturing, alliance management and intellectual property.

Before joining MorphoSys AG, Dr. Sproll held various R&D positions in the pharmaceutical industry, e.g. at the Vienna research facility of Boehringer Ingelheim and at E. Merck KGaA in Darmstadt, Germany, focusing on the discovery and development of antibody-based drugs and cancer vaccines.

Dr. Sproll studied Biology and was awarded a Doctor of Natural Sciences by the Technical University of Stuttgart, Germany. Before joining the industry, she held various research positions at different institutes of the Max-Planck Society in Tübingen, Germany.

 

Dr. Markus Enzelberger

Interim Chief Scientific Officer

Biography

Dr. Markus Enzelberger

Interim Chief Scientific Officer

Year of Birth 1969
Nationality Deutsch
Management Board Member of MorphoSys AG since 2017*
End of appointment 2017

*effective April 15, 2017

Dr. Enzelberger joined MorphoSys in 2002 and served in different leadership positions within R&D. Since 2012 he acted as Senior Vice President Discovery, Alliances and Technologies, taking responsibility for discovery programs for MorphoSys’s partners and MorphoSys’s proprietary pipeline as well as for the technology development. Dr. Enzelberger is co-inventor of the HuCAL Platinum and the Ylanthia libraries and worked on Guselkumab and many other programs within MorphoSys’s pipeline. His new areas of responsibility include discovery, technology development, protein sciences, manufacturing and alliance management.

Before joining MorphoSys, Dr. Enzelberger did his postdoc with Steven Quake at the California Institute of Technology on microfluidic biological assays, where he co-invented the key technologies of Fluidigm (South San Francisco, CA, USA).

Dr. Enzelberger studied Chemistry and was awarded a Doctor of Natural Sciences by the Technical University of Stuttgart, Germany. He performed his Diploma thesis together with Bayer and his PhD thesis with BASF on the use of enzymes in chemical processes.

Related links

Supervisory Board

The Supervisory Board oversees and advises the Management Board. The Board consists of professionally qualified members with many years of experience in the biotechnology and pharmaceutical industries.

Dr. Gerald Möller

Chairman

Biography and additional memberships

Dr. Gerald Möller

Chairman

Year of birth 1943
Nationality German
Place of residence Heidelberg, Germany

Professional Development

Currently

Chairman of the Supervisory Board of MorphoSys AG as well as member of another supervisory board and member of comparable domestic and foreign supervisory boards of commercial enterprises (see below)

2002– 2014 Advisor HBM Partners, Zug, Switzerland
1999 – 2000

CEO and Member of the Executive Committee, 4sigma Ltd., Bermuda

1998

Head of Development and Strategic Marketing Pharmaceuticals, Roche AG, Basel, Switzerland

1995 – 1998

CEO, Boehringer Mannheim Group, Amsterdam, The Netherlands

1994

CEO, Boehringer Mannheim Therapeutics, Mannheim, Germany

1992 – 1993

President, Advanced Diagnostics & Biochemicals, Boehringer Mannheim GmbH, Mannheim, Germany, as well as Chief Technical Officer, Corange Ltd., Bermuda

1988 – 1992

President, Decentralized Diagnostics, Boehringer Mannheim GmbH, Mannheim, Germany

1986 – 1987

President, Biochemicals & R&D, Boehringer Mannheim Corp, Indianapolis, IN, USA

1980 – 1985

Several functions in Diagnostic R&D, Boehringer Mannheim GmbH, Tutzing, Germany; 1985 Head of all Diagnostic R&D

1978 – 1979

Director, Scientific Department, Boehringer Mannheim Yamanaouchi K.K., Tokyo, Japan

1975 – 1977

Group Leader Quality Control, Boehringer Mannheim GmbH, Mannheim, Germany

Education

1975 PhD, Institute for Physical Chemistry, Kiel, Germany
1970 – 1975 Scientific assistant at the Institute for Physical Chemistry, Kiel, Germany
1970 Diploma in Chemistry, Institute for Physical Chemistry, Kiel, Germany
1965 – 1970 Student at University of Kiel, Chemistry, Kiel, Germany

Memberships in statutory supervisory boards and/or in comparable domestic or foreign supervisory bodies of commercial enterprises

4sigma Inc., Bermuda Chairman of the Board of Directors
Adrenomed AG, Germany Member of the Supervisory Board
Ayoxxa Biosystems GmbH, Germany Chairman of the Advisory Board
Invendo Medical GmbH, Germany Chairman of the Advisory Board

Dr. Möller is a member of MorphoSys AG's Supervisory Board since 1999.

Dr. Frank Morich

Deputy Chairman

Biography and additional memberships

Dr. Frank Morich

Deputy Chairman

Year of birth 1953
Nationality German
Place of residence Berlin, Germany

Professional Development

Currently

Self-employed business consultant in the life science and healthcare industries

2011 - 2014  Chief Commercial Officer and Member of the Board of Directors, Takeda Pharmaceutical Company Ltd., Tokyo, Japan, as well as CEO, Takeda Pharmaceutical International GmbH, Glattbrugg, Switzerland
2010 – 2011 Executive Vice President International Operations, Takeda Pharmaceutical International, Inc., Deerfield, IL, USA
2008 – 2010 CEO, NOXXON Pharma AG, Berlin, Germany
2005 – 2007 CEO and Member of the Board of Directors, Innogenetics N.V., Ghent, Belgium
2004 CEO and Chairman of the Executive Board, AM-Pharma B.V., Utrecht, The Netherlands
2003 – 2004 Independent consultant for the venture capital, life sciences and health care industries
2002 Chairman of the Board of Management and Chairman of the Executive Committee, Bayer HealthCare AG, Leverkusen, Germany
2000 – 2002 Member of the Board of Management, Bayer AG, Leverkusen, Germany
1993 – 2000 General Manager Consumer Care Division, Head of Global Product Development and Head of Research and Development, Bayer AG, Leverkusen, Germany
1991 – 1993 Director Clinical Research (CNS), Miles Inc., West Haven, CT, USA
1982 – 1991 Head of Institute of Biochemistry, Head of Institute of Pharmacology, Laboratory Head/Head of Cellular/In-Vitro Research, Institute of Pharmacology, Bayer AG, Wuppertal, Germany
1979 - 1980 Staff Physician, German Army, Marburg, Germany

Education

1992

“Managing for Global Success” Executive Development Program, Columbia University, NY, USA

1980 – 1982 Postdoctoral Fellow, Institute of Experimental Immunology, University of Marburg, Germany
1979 Dissertation & MD degree as physician and registered to practice medicine
1972 – 1979 Medical studies at the University of Marburg, Germany

Memberships in statutory supervisory boards and/or in comparable domestic or foreign supervisory bodies of commercial enterprises

Currently no further memberships.

Dr. Morich is a member of MorphoSys AG's Supervisory Board since 2015.

Dr. Marc Cluzel

Member

Biography and additional memberships

Dr. Marc Cluzel

Member

Year of birth 1955
Nationality French
Place of residence Montpellier, France

Professional Development

Currently

Member of the Supervisory Board of MorphoSys AG as well as member of a comparable foreign supervisory board of a commercial enterprise (see below)

2011 – 2012

Executive Vice President of Product Development, HÙYÀ Bioscience International, LLC, San Diego, CA, USA

2009 - 2010

Executive Vice President of Research & Development, Sanofi-Aventis S.A., Paris, France

2007 – 2009

Senior Vice President of Science and Medical Affairs, Sanofi-Aventis S.A., Paris, France

2002 – 2011

Chairman and CEO, Sanofi-Aventis R&D France, Paris, France

1996 – 2001

Head of Project Direction, Sanofi R&D France, Paris, France

1993 – 1996

Project Director, Sanofi R&D France, Paris, France

1991 – 1993

Clinical Pharmacologist, Sanofi R&D France, Montpellier, France

Education

1983 – 1990 Ph.D. Biochemistry at University of Montpellier, France
1973 – 1985 M.D., Study of Medicine at University of Montpellier, France

Memberships in statutory supervisory boards and/or in comparable domestic or foreign supervisory bodies of commercial enterprises

Moleac Pte. Ltd., Singapore Member of the Board of Directors

Dr. Cluzel is a member of MorphoSys AG's Supervisory Board since 2012.

Krisja Vermeylen

Member

Biography and additional memberships

Krisja Vermeylen

Member

Year of birth 1962
Nationality Belgisch
Place of residence Hellerup, Denmark

Professional Development

Currently Senior Vice President Corporate People & Organisation, Novo Nordisk A/S, Bagsvaerd, Denmark
2013 – 2015

Corporate Vice President and General Manager (CVP), Novo Nordisk Pharma GmbH, Mainz, Germany

2008 – 2013

Vice President (France & BeLux), Novo Nordisk SA, Paris, France

2002 – 2013

Vice President Europe West (France, Belgium, Luxembourg, Netherlands), Novo Nordisk SA, Paris, France

1998 – 2002

General Manager (BeLux & Director GHT France), Novo Nordisk SA, Brussels, Belgium

1997 – 1998

Marketing & Sales Manager Diabetes/Women Health Care/Growth Hormone/Haemophilia, Novo Nordisk SA, Brussels, Belgium

1997

Marketing Manager Diabetes/Women Health Care/Growth Hormone, Novo Nordisk SA, Brussels, Belgium

1996 – 1997

Senior Product Manager Anaesthesia and Cardiovascular, Pharmacia & Upjohn, Brussels, Belgium

1995 Product & Sales Manager Low molecular weight heparin, Pharmacia, Brussels, Belgium
1994 – 1995 Product Manager Anaesthesia and Cardiovascular, Pharmacia, Brussels, Belgium
1993 – 1994 Product Manager Anaesthesia, Pharmacia, Brussels, Belgium
1991 – 1993 Medical Representative Hospital Division Parenteral Nutrition, Kabi Pharmacia, Brussels, Belgium
1986 – 1991 Pharmacist dispenser

Education

1985 – 1986 Doctoral student of bromatology at the University of Antwerp (UIA), Antwerp, Belgium
1980 –  1985 Pharmacist / Master in pharmaceutical sciences at the University of Antwerp (UIA, RUCA), Antwerp, Belgium

Memberships in statutory supervisory boards and/or in comparable domestic or foreign supervisory bodies of commercial enterprises

Currently no memberships.

Krisja Vermeylen is a member of MorphoSys AG's Supervisory Board since 2017.

Wendy Johnson

Member

Biography and additional memberships

Wendy Johnson

Member

Year of birth 1952
Nationality US-American
Place of residence San Diego, CA, USA

Professional Development

Currently

Managing Director, Gemini Advisors, San Diego, CA, USA;
Interim Chief Operating Officer, AmpliPhi Biosciences Corp., Glen Allen, VA, USA

2007 – 2014 Founder, President and CEO, Aires Pharmaceuticals, Inc., San Diego,
CA, USA
2005 – 2014 Venture Partner, ProQuest Investments, San Diego, CA, USA
2001 – 2005 Senior Vice President Corporate Development, Salmedix, Inc., San Diego, CA, USA
2000 – 2001 Independent Consultant, San Diego, CA, USA
2000 – 1998

Vice President Business Development, Women First HealthCare, San Diego, CA, USA

1998 – 1994 Vice President Corporate Development & Operations, Selective Genetics, San Diego, CA, USA
1994 – 1990 Vice President Business Development & Regulatory Affairs, Cytel Corp., San Diego, CA, USA
1990 – 1998 Manager Business Development, Synbiotics Corp., San Diego, CA, USA
1988 – 1986 International Business Development & Regulatory Affairs Manager, Murex Corp., Cambridge, Great Britain
1986 – 1976 Assistant Director, US Food & Drug Administration, Center for Devices & Radiological Health, Rockville, MD, USA

Education

1986 – 1984

M.B.A., Loyola Marymount University, Los Angeles, CA, USA

1976 – 1974 M.S. Clinical Microbiology, Hahnemann University Hospital, Philadelphia, PA, USA
1974 – 1970 B.S. Microbiology, University of Maryland, College Park, MD, USA

Memberships in statutory supervisory boards and/or in comparable domestic or foreign supervisory bodies of commercial enterprises

AmpliPhi Biosciences Corp. Member of the Board of Directors

Wendy Johnson is a member of MorphoSys AG's Supervisory Board since 2015.

Klaus Kühn

Member

Biography and additional memberships

Klaus Kühn

Member

Year of birth 1952
Nationality German
Place of residence Grevenbroich, Germany

Professional Development

Currently

Member of the Supervisory Board of MorphoSys AG as well as member of comparable supervisory boards of commercial enterprises (see below)

2002 – 2010 CFO, Bayer AG, Leverkusen, Germany
1998 – 2002 Head of Finance, Bayer AG, Leverkusen, Germany
1981 – 1998 Head of Corporate Staff as well as Head of Finance, Schering AG, Berlin, Germany, and Columbus, OH, USA
1979 – 1981 IT Systems Engineering, Siemens AG, Berlin, Germany

Education

1987 – 1989

MBA in International Business Studies, University of South Carolina, Columbia, SC, USA

1972 – 1978 Diploma in Mathematics/Physics, Technical University Berlin, Germany

Memberships in statutory supervisory boards and/or in comparable domestic or foreign supervisory bodies of commercial enterprises

Flossbach von Storch AG Chairman of the Supervisory Board
Hella KGaA Hueck & Co. Member of the Supervisory Board, Member of the Shareholder Committee

Klaus Kühn is a member of MorphoSys AG's Supervisory Board since 2015.

Composition of the Supervisory Board

  Initial
Appointment
End of
Period
Audit
Committee
Remuneration and Nomination
Committee
Science
and Technology
Committee
Dr. Gerald Möller 1999 2018  
 
Dr. Marc Cluzel 2012 2018  
Krisja Vermeylen 2017 2019
 
Wendy Johnson 2015 2020
 
Klaus Kühn
2015 2020
   
Dr. Frank Morich 2015 2020    

Independent Financial Expert     Chairperson     Member